Abilify Maintena Kit - (300, 400 mg/vial ; Extended-release Injectable Suspension)

Generic Name	Aripiprazole	Innovator	Otsuka
Dosage	300, 400 mg/vial ; Extended-release Injectable Suspension	Branded US Sales	More Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	None
Indication	ABILIFY MAINTENA is an atypical antipsychotic indicated for the treatment of schizophrenia.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*****	*** \ ***	*** **, ****	*******	********	******* *** **** *** **** ****
*** ******	** \ **	*** **, ****	*******	****	*** ****** *** ****
******	** \ **	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events